Menactra Vaccine 0.5 ml is a combination vaccine that protects against meningococcal disease caused by group A, C, Y and W-135 strains of Neisseria meningitidis and diphtheria, a serious bacterial infection that can cause a thick coating in the back of the throat, airway obstruction and other serious complications. The Menactra Vaccine is usually given to adults, adolescents, children and infants >2 months of age, as well as people who are at increased risk of contracting these infections.
The Menactra Vaccine must be administered by a healthcare professional and it's important to complete all doses to ensure full protection. People aged 15-55 who are at continuing risk of meningococcal disease may be given a booster dose after 4-6 years. The Menactra 0.5 ml should not be administered by the intravenous, subcutaneous or intradermal routes.
The Menactra Vaccine 0.5 ml may cause side effects such as injection site reactions (pain, swelling, redness), irritability, loss of appetite, drowsiness, headache, nausea, vomiting and diarrhoea. If these persist or get worse, tell your doctor who may suggest ways to relieve them.
Inform your doctor of all pre-existing medical conditions and medications before taking Menactra Vaccine 0.5 ml and consult a doctor if you are pregnant or breastfeeding.
Prevention of Meningococcal disease: Menactra Vaccine is used in the prevention of meningococcal disease is a serious bacterial infection that affects the lining of the brain and spinal cord (meninges) and can also cause blood infections. The most common form of the disease is meningococcal meningitis, which is characterized by symptoms such as severe headache, fever, stiff neck, and a rash.
Menactra Vaccine Reduce the risk of contracting meningococcal disease, which can be fatal if not treated promptly.
Menactra Vaccine 0.5 ml Protects against four strains of bacteria that cause meningococcal disease (groups A, C, Y and W-135) and also protects against diphtheria, a serious bacterial infection of the throat that can cause serious complications such as heart and nerve damage.
As with all medicines, Menactra Vaccine 0.5 ml may cause side effects that do not require medical attention and will disappear as your body adjusts to the medicine. Tell your doctor if they persist or if you're worried about them.
Menactra Vaccine is administered by a healthcare professional or nurse in a hospital or clinic setting. The specific dosage and administration of Menactra 0.5 ml will depend on the clinical condition, age and medical history of the patient and other factors. Do not self-administer.
Menactra Vaccine 0.5 ml works by introducing a small piece of the meningococcal bacteria, called an antigen, into the body. This causes the immune system to produce antibodies against the antigen, which can then recognise and attack the actual bacteria when they enter the body. This Menactra 0.5 ml contains antigens for several types of meningococcal bacteria, such as groups A, C, Y and W-135. Diphtheria toxoid is a toxoid used in the vaccine to protect against diphtheria. Diphtheria toxoid is inactivated by treatment with formaldehyde, making it safe for use in a vaccine. The Menactra Vaccine can be used in combination with the meningococcal vaccine to protect against both diseases with a single vaccination.
It is generally not recommended to drink alcohol while taking Menactra Vaccine. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
Menactra 0.5 ml should be used with caution in patients with Kidney disease. It is important that patients with kidney disease closely monitor kidney function while taking Menactra Vaccine 0.5 ml and report any unusual symptoms or changes in kidney function to their doctor. The dose of Menactra Vaccine 0.5 ml may need to be adjusted in patients with kidney disease.
Menactra Vaccine 0.5 ml should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Menactra 0.5 ml and report any unusual symptoms or changes in liver function to their doctor. The dose of Menactra Vaccine 0.5 ml may need to be adjusted in patients with liver disease.
Use of Menactra Vaccine may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Menactra 0.5 ml during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
It is not recommended to breastfeed while taking Menactra Vaccine 0.5 ml. Menactra Vaccine may pass into breast milk and harm the infant. If you are breastfeeding and taking Menactra Vaccine 0.5 ml, it is important to talk to your doctor about the possible risks and benefits of continuing to breastfeed. Your doctor will be able to help you make the best decision for you and your baby's health.
It is uncertain if the Menactra Vaccine affects one's ability to drive. If any symptoms that impair focus and reaction occur, do not operate a vehicle.
1. MENINGOCOCCAL (GROUPS A, C, Y AND W-135) POLYSACCHARIDE DIPHTHERIA TOXOID CONJUGATE VACCINE, Sanofi Healthcare India Pvt. Ltd [Updated: Dec 2021], Product Leaflet
2. Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection, Sanofi Pasteur Inc, US FDA, Product Leaflet
3. Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Pharmacy Retailing (NZ) Ltd. [Updated 20 June 2022], Product Monograph